AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ENDEAVOR BIOMEDICINES · Biotechnology & therapeutics

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 16, 2025

Income

$51,000.00

What the client paid this registrant for the period.

Client based in

California

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Health Issues

RESULT Act FDA Modernization

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.